Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary systemic amyloidosis.

R L Comenzo1

  • 1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Primary systemic amyloid light-chain (AL) amyloidosis diagnosis involves identifying clonal plasma cells and amyloid deposits. Autologous stem cell transplant offers durable remission for eligible patients, but risks exist for those with advanced cardiac involvement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells.

Biochemistry and biophysics reports·2025
Same author

Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.

Bone marrow transplantation·2017
Same author

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

Leukemia·2016
Same author

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Leukemia·2016
Same author

siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases.

Gene therapy·2016
Same author

Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis.

Bone marrow transplantation·2014
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Nephrology

Background:

  • Systemic amyloid light-chain (AL) amyloidosis presents with diverse organ dysfunction, including heart failure, hepatomegaly, nephrotic syndrome, and neuropathy.
  • Early diagnosis is crucial for effective management and improved patient outcomes.

Purpose of the Study:

  • To outline diagnostic strategies for AL amyloidosis.
  • To review treatment recommendations, focusing on autologous hematopoietic stem cell transplantation (ASCT) and alternative therapies.

Main Methods:

  • Diagnostic evaluation includes serum/urine immunofixation, bone marrow biopsy with immunophenotyping, and tissue biopsy for amyloid confirmation.
  • ASCT eligibility criteria emphasize adequate organ function (cardiac, pulmonary, hepatic).

Related Experiment Videos

Main Results:

  • ASCT can lead to durable remissions and organ function improvement in AL amyloidosis patients.
  • Patients with dominant cardiac amyloid face increased peritransplant mortality risk, necessitating careful selection.
  • Alternative treatments like oral melphalan and prednisone have lower response rates, highlighting the need for clinical trials.

Conclusions:

  • A systematic diagnostic approach is essential for AL amyloidosis.
  • ASCT is a valuable treatment for select patients, but risk stratification is critical.
  • Emerging therapies are needed for patients ineligible for ASCT or with advanced disease.